SHR-A2102
- Generic Name
- SHR-A2102
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Adebelimab InjectionDrug: Ametinib Mesylate Tablets
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06895928
- Locations
- 🇨🇳
Shanxi Cancer hospital, Taiyuan, Shanxi, China
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2
Recruiting
- Conditions
- Advanced Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer (TNBC)HER2-negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT06649331
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06639347
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT06589778
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SHR-A2102 ; Adebrelimab injection
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06417554
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- Advanced Or Metastatic Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT05735275
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 395
- Registration Number
- NCT05701709
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- HER2-negative Breast CancerAdvanced Breast CancerBreast NeoplasmBreast CancerHormone Receptor Positive Tumor
- Interventions
- Drug: AKT inhibitorDrug: CarrelizumabDrug: SHR-1167Drug: TPCDrug: SHR-6209
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath